Compare Illumina, Inc. (ILMN) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Oklo Inc — how do they compare? Illumina, Inc. trades at $190.04 (market cap $27.94B), while Oklo Inc trades at $43.59 (market cap $7.22B). The key difference: Illumina, Inc. is far larger — about 3.9× Oklo Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | OKLO | |
|---|---|---|
Market Cap | $27.94B | $7.22B |
Sector | Health | Technology |
52-Week High | $194.33 | $174.14 |
52-Week Low | $91.00 | $41.11 |
Enterprise Value | $29.33B | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
OKLO trades at $41.51, down 42% year-to-date amid regulatory uncertainty and recent stock dilution. The company shows strong analyst support with 77% buy ratings and a $90.88 consensus price target, but fundamentals remain weak with negative earnings and cash flow. Recent news highlights progress on nuclear projects but regulatory hurdles persist.
OKLO presents high-risk/high-reward potential with significant upside to analyst targets but faces execution risks and negative profitability. The stock's bearish technical signals contrast with bullish long-term nuclear energy thesis. Regulatory approvals and Meta partnership execution remain critical catalysts for valuation recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
